dHER2+AS15

dHER2+AS15 is a cancer vaccine composed of a truncated recombinant HER2/neu peptide (dHER2) combined with the immunoadjuvant AS15. The vaccine is designed to stimulate an immune response against HER2-overexpressing tumor cells, primarily in breast cancer. The mechanism involves inducing both humoral and cellular immunity targeting the HER2 antigen, which is commonly overexpressed in certain types of breast cancer. The AS15 adjuvant system enhances the immunogenicity of the truncated HER2 protein by providing additional immune stimulation through its liposomal formulation containing three immunostimulatory components. Clinical studies have shown that this combination can induce durable antibody responses and has an acceptable safety profile in patients with early-stage or metastatic HER2-positive breast cancer who are resistant to trastuzumab[1][3][7]. The drug was initially developed by GSK.

Other names

dHER2 protein with AS15 adjuvantdHER-2 protein with AS15 adjuvantdHER 2 protein with AS15 adjuvant